Ultragenyx (RARE) Moves 15.5% Higher: Will This Strength Last?

Company Overview - Ultragenyx shares increased by 15.5% to $22.78, following a significant trading volume, despite a prior 40.9% loss over the last four weeks [1] - The stock's rally is attributed to optimism regarding the completion of the rolling submission of a biologics license application (BLA) to the FDA for its AAV gene therapy, DTX401, aimed at treating glycogen storage disease type Ia (GSDIa) [2] Financial Performance - The company is projected to report a quarterly loss of $1.32 per share, reflecting a year-over-year increase of 5%, with expected revenues of $186.9 million, marking a 13.4% rise from the previous year [3] - The consensus EPS estimate for Ultragenyx has remained stable over the past 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Ultragenyx is categorized within the Zacks Medical - Biomedical and Genetics industry, where another company, Insmed, experienced a 1.3% decline to $174.09 and has seen a -16.6% return over the past month [5] - Insmed's consensus EPS estimate has increased by 4.4% over the past month to -$1.33, which is a 0.8% decrease from the previous year's report [6]